Illustrative image – not actual.
Biocon, a biopharmaceutical company, announced that the Board of its subsidiary Biocon Biologics has approved a primary equity investment by Abu Dhabi-based ADQ.
As per the terms of the proposed agreement, ADQ will invest Rs 555 crore for 1.80 percent minority stake in the Biosimilar business, valuing Biocon Biologics at a post-money valuation of approximately USD 4.17 billion.
The transaction is subject to customary condition precedents and approvals. Post the completion of this transaction, Biocon will hold 89.89 percent stake in Biocon Biologics on a fully diluted basis.
Biocon Biologics had raised over USD 255 million from global marquee investors from January to November 2020.
The company has raised USD 75 million through a primary equity infusion by True North Fund for 2.44 percent stake; Tata Capital Growth Fund picked up 0.85 percent stake for USD 30 million.
Goldman Sachs made a capital injection of USD 150 million in exchange for optionally convertible debentures of Biocon Biologics.
